Featured Platforms

Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms


Launching A New Era in Antibody Drug Development

6-18 months faster development and no CMC challenges

WuXiBody™ is an innovative, proprietary technology platform developed by WuXi Biologics for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 6-18 months and significantly reduce cost-of-goods.  The WuXiBody™ platform enables almost any monoclonal antibody (mAb) sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).

WuXiBody™ Development/CMC Advantages

  • Saves 6-18 months of development time
  • Reduces manufacturing costs by as much as 90%
  • High protein expression in CHO cells (5 – 16 g/L)
  • No aggregation issues
  • Can be used in both fed-batch and concentrated fed-batch production
  • Very stable: >2 weeks in serum at 37 °C
  • No solubility issues: > 30 mg/ml

WuXiBody™ Bispecific Engineering Advantages

  • Compatible with almost any mAb sequence
  • Available in both symmetric and asymmetrical formats
  • Accommodate different valency formats (bi, tri and tetra) based on project needs and biology
  • Same purification schemes as mAbs
  • In vivo half-life similar to mAbs
  • Expected low immunogenicity (utilizes natural sequence without complicated engineering)